Issue Date: October 22, 2012
GSK Will Spare Irish Facility
GlaxoSmithKline has decided to keep operating a pharmaceutical manufacturing plant in Sligo, Ireland, that had been slated for closure. GSK got the plant in 2009 as part of its acquisition of the skin disease treatment firm Stiefel. With support from IDA Ireland, the country’s business development agency, GSK will invest about $13 million to convert the plant into a personal care products facility. Employment will decrease from 180 today to 120 during a two-year transition period, but GSK says 50 jobs will be added at that point.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society